Skip to content

Resection of the Esophagus and Subsequent Weight Loss

The Effect of Clinical Treatment for Unintentional Weight Loss on Food Reward and Appetitive Behaviour in Patients Who Have Lost >10% of Their Body Weight After Undergoing Curative Surgery for Oesophageal Cancer

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03377660
Acronym
REWARD
Enrollment
30
Registered
2017-12-19
Start date
2018-01-01
Completion date
2023-06-01
Last updated
2024-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer, Weight Gain, Eating Behavior, Food Reward

Keywords

Esophagectomy, Unintentional weight loss, Gut hormones

Brief summary

The investigators aim to ascertain how food reward signals and eating behaviour relates to the gut-brain pathway in weight-losing patients after curative surgery for oesophageal cancer, and how this pathway responds to clinical treatment for this unintentional weight loss. The primary outcomes are the blood oxygen level dependent (BOLD) signal on functional MRI (fMRI), and the breakpoint during the progressive ratio task (PRT - a measure of eating behaviour), how these differ in response to multiple clinical treatment options, as well as how they relate to weight gain while on treatment.

Detailed description

The incidence of cancer of the oesophagus (food pipe) is increasing. Improvements in treatment strategies have resulted in more people who remain free from cancer recurrence in the long term following treatment. Surgery is the cornerstone of treatment for patients with oesophageal cancer, but while surgical removal of the tumour (oesophagectomy) may offer the best chance of cure, these are major operations associated with specific long term complications. Poor appetite, weight loss and nutritional impairment are common problems among patients who attain long-term cancer remission and cure after surgery. A new clinic has been established to treat patients who are in remission but who have lost more than 10% of their body weight secondary to the effects of the surgery and struggling to regain weight. These patients will be treated as per standard of care with medications to aid weight gain. The investigators are interested to conduct research into how the reward value of food changes during the clinical treatment pathway. The hypothesis is that there will be an increased reward response to food after medication use, the magnitude of which will correlate with weight gain. To assess this, patients who are already part of this clinic will be approached to have fMRI that can demonstrate changes in brain reward centres as well as a Progressive Ratio Task, which is a direct measure of appetitive behaviour. Changes in brain reward centre responses and appetitive behaviour will be correlated with changes in weight after pharmacotherapy. This may further inform future clinical protocols to provide improved precision medicine.

Interventions

Patients undergo clinical treatment as indicated, they are studied before and after.

Sponsors

University College Dublin
CollaboratorOTHER
St. James's Hospital, Ireland
CollaboratorOTHER
Imperial College London
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. History of esophagectomy with gastric conduit reconstruction 2. Recurrence-free at least 12 months post-operatively 3. Weight loss ≥10% from premorbid weight, or requiring ongoing caloric supplementation 4. Due to undergo clinical treatment for weight loss with Sandostatin or Mirtazapine

Exclusion criteria

1. Pregnancy, breastfeeding 2. Significant and persistent chemoradiotherapy and/or surgical complication 3. Other active malignancy 4. Exocrine pancreatic insufficiency detected using fecal elastase 5. Uncontrolled diabetes mellitus 6. Significant psychiatric disorder or cognitive decline or communication impairment limiting capacity to provide informed consent 7. Severe dysphagia 8. Other disease or medication which may impact gut hormone physiology 9. History of significant food allergy, certain dietary restrictions 10. Any definite contraindication to somatostatin analogue administration 11. Claustrophobia, or any absolute contraindication to MRI scanning 12. Metallic implants, precluding fMRI

Design outcomes

Primary

MeasureTime frameDescription
Change in BOLD signalBefore and after 4 weeks of clinical treatmentMeasure of food reward on fMRI
Change in breakpoint at PRTBefore and after 4 weeks of clinical treatmentMeasure of drive to eat

Secondary

MeasureTime frameDescription
Correlation of weight change during treatment with PRT breakpoint changesBefore and after 4 weeks of clinical treatmentRelationship of eating behaviour changes to weight gain
Correlation of weight change during treatment with BOLD signal changesBefore and after 4 weeks of clinical treatmentRelationship of food reward changes to weight gain

Countries

Ireland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026